Skip to main content

Advertisement

SpringerLink
Log in

Challenges in the treatment of hormone receptor-positive, HER2-negative metastatic breast cancer with brain metastases

  • Clinical
  • Published:
Cancer and Metastasis Reviews Aims and scope Submit manuscript

Abstract

Brain metastases are a major cause of morbidity and mortality for women with hormone receptor (HR)-positive breast cancer, yet little is known about the optimal treatment of brain disease in this group of patients. Although these patients are at lower risk for brain metastases relative to those with HER2-positive and triple-negative disease, they comprise the majority of women diagnosed with breast cancer. Surgery and radiation continue to have a role in the treatment of brain metastases, but there is a dearth of effective systemic therapies due to the poor penetrability of many systemic drugs across the blood-brain barrier (BBB). Additionally, patients with brain metastases have long been excluded from clinical trials, and few studies have been conducted to evaluate the safety and effectiveness of systemic therapies specifically for the treatment of HER2-negative breast cancer brain metastases. New approaches are on the horizon, such as nanoparticle-based cytotoxic drugs that have the potential to cross the BBB and provide clinically meaningful benefits to patients with this life-threatening consequence of HR-positive breast cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Sneed, P.K., Kased, N., & Rubenstein, J.L. (2014). Brain metastases and neoplastic meningitis. In J.E. Neiderhuber, J.O. Armitage, J.H. Doroshow, M. B. Kastan & J. E. Tepper (Eds.), Abeloff’s Clinical Oncology (pp. 725–738.e4). Philadelphia: Elsevier.

  2. Bartsch, R., Berghoff, A. S., & Preusser, M. (2013). Optimal management of brain metastases from breast cancer. Issues and considerations. CNS Drugs, 27(2), 121–134.

    Article  CAS  PubMed  Google Scholar 

  3. Sperduto, P. W., Kased, N., Roberge, D., Xu, Z., Shanley, R., Luo, X., et al. (2012). Effect of tumor subtype on survival and the graded prognostic assessment for patients with breast cancer and brain metastases. International Journal of Radiation Oncology, Biology, and Physics, 82(5), 2111–2117.

    Article  Google Scholar 

  4. Arvold, N. D., Oh, K. S., Niemierko, A., Taghian, A. G., Lin, N. U., Abi-Raad, R. F., et al. (2012). Brain metastases after breast-conserving therapy and systemic therapy: incidence and characteristics by biologic subtype. Breast Cancer Research and Treatment, 136(1), 153–160.

    Article  PubMed  Google Scholar 

  5. Puhalla, S., Elmquist, W., Freyer, D., Kleinberg, L., Adkins, C., Lockman, P., et al. (2015). Unsanctifying the sanctuary: challenges and opportunities with brain metastases. Neuro-Oncology, 17(5), 639–651.

    Article  PubMed  PubMed Central  Google Scholar 

  6. Kodack, D. P., Askoxylakis, V., Ferraro, G. B., Fukumura, D., & Jain, R. K. (2015). Emerging strategies for treating brain metastases from breast cancer. Cancer Cell, 27(2), 163–175.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Howlander, N., Altekruse, S.F., Li, C.I., Chen, V.W., Clarke, C.A., Ries, L.A., et al. (2014). US incidence of breast cancer subtypes defined by joint hormone receptor and HER2 status. Journal of the National Cancer Institute, 106(5). doi:10.1093/jnci/dju055.

  8. Kennecke, H., Yerushalmi, R., Woods, R., Cheang, M. C., Voduc, D., Speers, C. H., et al. (2010). Metastatic behavior of breast cancer subtypes. Journal of Clinical Oncology, 28(20), 3271–3277.

    Article  PubMed  Google Scholar 

  9. Niwinska, A., Murawska, M., & Pogoda, K. (2010). Breast cancer brain metastases: differences in survival depending on biological subtype, RPA RTOG prognostic class and systemic treatment after whole-brain radiotherapy (WBRT). Annals of Oncology, 21(5), 942–948.

    Article  CAS  PubMed  Google Scholar 

  10. Sperduto, P. W., Kased, N., Roberge, D., Xu, Z., Shanley, R., Luo, X., et al. (2012). Summary report on the graded prognostic assessment: an accurate and facile diagnosis-specific tool to estimate survival for patients with brain metastases. Journal of Clinical Oncology, 30(4), 419–425.

    Article  PubMed  Google Scholar 

  11. Ramakrishna, N., Temin, S., Chandarlapaty, S., Crews, J. R., Davidson, N. E., Esteva, F. J., et al. (2014). Recommendations on disease management for patients with advanced human epidermal growth factor receptor 2-positive breast cancer and brain metastases: American Society of Clinical Oncology clinical practice guideline. Journal of Clinical Oncology, 32(19), 2100–2108.

    Article  PubMed  Google Scholar 

  12. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: central nervous system tumors v.1.2015. Accessed September 28, 2015.

  13. Tallet, A. V., Azria, D., Barlesi, F., Spano, J. P., Carpentier, A. F., Gonçalves, A., et al. (2012). Neurocognitive function impairment after whole brain radiotherapy for brain metastases: actual assessment. Radiation Oncology. doi:10.1186/1748-717X-7-77.

    PubMed  PubMed Central  Google Scholar 

  14. Tallet, A. V., Azria, D., Le Rhun, E., Barlesi, F., Carpentier, A. F., Gonçalves, A., et al. (2014). Rationale for the use of upfront whole brain irradiation in patients with brain metastases from breast cancer. International Journal of Molecular Sciences, 15(5), 8138–8152.

    Article  PubMed  PubMed Central  Google Scholar 

  15. Scoccianti, S., & Ricardi, U. (2012). Treatment of brain metastases: review of phase III randomized controlled trials. Radiotherapy and Oncology, 102(2), 168–179.

    Article  PubMed  Google Scholar 

  16. Chang, E. L., Wefel, J. F., Hess, K. R., Allen, P. L., Lang, F. F., Kornguth, D. G., et al. (2009). Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole-brain irradiation: a randomised controlled trial. Lancet Oncology, 10(11), 1037–1044.

    Article  PubMed  Google Scholar 

  17. Aoyam, H., Tago, M., Kato, N., Toyoda, T., Kenjyo, M., Hirota, S., et al. (2007). Neurocognitive function of patients with brain metastasis who received either whole brain radiotherapy plus stereotactic radiosurgery or radiosurgery alone. International Journal of Radiation Oncology Biology Physics, 68(5), 1388–1395.

    Article  Google Scholar 

  18. Li, J., Bentzen, S. M., Renschler, M., & Mehta, M. P. (2007). Regression after whole brain radiation therapy for brain metastases correlates with survival and improved neurocognitive function. Journal of Clinical Oncology, 25(10), 1260–1266.

    Article  PubMed  Google Scholar 

  19. Brown, P.D., Asher, A.L., Ballman, K.V., Farace, E., Cerhan, J.H., Anderson, S.K., et al. (2015). NCCTG N0574 (Alliance): a phase III randomized trial of whole brain radiation therapy (WBRT) in addition to radiosurgery (SRS) in patients with 1 to 3 brain metastases. Journal of Clinical Oncology, 33(suppl), abstr LBA4.

  20. Ryken, T. C., McDermott, M., Robinson, P. D., Ammirati, M., Andrews, D. W., Asher, A. L., et al. (2010). The role of steroids in the management of brain metastases: a systematic review and evidence-based clinical practice guideline. Journal of Neuro-Oncology, 96(1), 103–114.

    Article  CAS  PubMed  Google Scholar 

  21. Brown, P. D., Pugh, S., Laack, N. M., Wefel, J. S., Khuntia, D., Meyers, C., Radiation Therapy Oncology Group (RTOG), et al. (2013). Memantine for the prevention of cognitive dysfunction in patients receiving whole-brain radiotherapy: a randomized, double-blind, placebo-controlled trial. Neuro-Oncology, 15(10), 1429–1437.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. ClinicalTrials.gov Web site. Memantine hydrochloride and whole-brain radiotherapy with or without hippocampal avoidance in reducing neurocognitive decline in patients with brain metastases. Available at: https://clinicaltrials.gov/ct2/show/NCT02360215. Accessed September 29, 2015.

  23. Lien, E. A., Wester, K., Lønning, P. E., Solheim, E., & Ueland, P. M. (1991). Distribution of tamoxifen and metabolites into brain tissue and brain metastases in breast cancer patients. British Journal of Cancer, 63(4), 641–645.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Fine, R. L., Chen, J., Balmaceda, C., Bruce, J. N., Huang, M., Desai, M., et al. (2006). Randomized study of paclitaxel and tamoxifen deposition into human brain tumors: implications for the treatment of metastatic brain tumors. Clinical Cancer Research, 12(19), 5770–5776.

    Article  CAS  PubMed  Google Scholar 

  25. Carey, R. W., Davis, J. M., & Zervas, N. T. (1981). Tamoxifen-induced regression of cerebral metastases in breast carcinoma. Cancer Treatment Reports, 65(9–10), 793–795.

    CAS  PubMed  Google Scholar 

  26. Colomer, R., Casas, D., Del Campo, J., Boada, M., Rubio, D., & Salvador, L. (1988). Brain metastases from breast carcinoma may respond to endocrine therapy. Breast Cancer Research and Treatment, 12(1), 83–86.

    Article  CAS  PubMed  Google Scholar 

  27. Pors, H., von Eyben, F., Sorensen, O., & Larsen, M. (1991). Long term remission of multiple brain metastases with tamoxifen. Journal of Neurooncology, 10(2), 173–177.

    Article  CAS  Google Scholar 

  28. Salvati, M., Cervoni, L., Innocenzi, G., & Bardella, L. (1993). Prolonged stabilization of multiple and single brain metastases from breast cancer with tamoxifen. Report of three cases. Tumori, 79(5), 359–362.

    CAS  PubMed  Google Scholar 

  29. Stewart, D. J., & Dahrouge, S. (1995). Response of brain metastases from breast cancer to megestrol acetate: a case report. Neuro-Oncology, 24(3), 299–301.

    Article  CAS  Google Scholar 

  30. Madhup, R., Kirti, S., Bhatt, M., Srivastava, P., Srivastava, M., & Kumar, S. (2006). Letrozole for brain and scalp metastases from breast cancer—a case report. Breast, 15(3), 440–442.

    Article  CAS  PubMed  Google Scholar 

  31. Cocconi, G., Lottici, R., Bisagni, G., Bacchi, M., Tonato, M., Passalacqua, R., et al. (1990). Combination therapy with platinum and etoposide of brain metastases from breast carcinoma. Cancer Investigation, 8(3–4), 327–334.

    Article  CAS  PubMed  Google Scholar 

  32. Franciosi, V., Cocconi, G., Michiara, M., Di Costanzo, F., Tonato, M., Carlini, P., et al. (1999). Front-line chemotherapy with cisplatin and etoposide for patients with brain metastases from breast carcinoma, non-small cell lung carcinoma, or malignant melanoma: a prospective study. Cancer, 85(7), 1599–1605.

    Article  CAS  PubMed  Google Scholar 

  33. Ekenel, M., Hormigo, A. M., Peak, S., Deangelis, L. M., & Abrey, L. E. (2007). Capecitabine therapy of central nervous system metastases from breast cancer. Journal of Neuro-Oncology, 85(2), 223–227.

    Article  CAS  PubMed  Google Scholar 

  34. Lassman, A. B., Abrey, L. E., Shah, G. D., Panageas, K. S., Begemann, M., Malkin, M. G., et al. (2006). Systemic high-dose intravenous methotrexate for central nervous system metastases. Journal of Neuro-Oncology, 78(3), 255–260.

    Article  CAS  PubMed  Google Scholar 

  35. Christodoulou, C., Bafaloukos, D., Kosmidis, P., Samantas, E., Bamias, A., Papakostas, P., Hellenic Cooperative Oncology Group, et al. (2001). Phase II study of temozolomide in heavily pretreated cancer patients with brain metastases. Annals of Oncology, 12(2), 249–254.

    Article  CAS  PubMed  Google Scholar 

  36. Abrey, L. E., Olson, J. D., Raizer, J. J., Mack, M., Rodavitch, A., Boutros, D. Y., et al. (2001). A phase II trial of temozolomide for patients with recurrent or progressive brain metastases. Journal of Neuro-Oncology, 53(3), 259–265.

    Article  CAS  PubMed  Google Scholar 

  37. Antonadou, D., Paraskevaidis, M., Sarris, G., Coliarakis, N., Economou, I., Karageorgis, P., et al. (2002). Phase II randomized trial of temozolomide and concurrent radiotherapy in patients with brain metastases. Journal of Clinical Oncology, 20(17), 3644–3650.

    Article  CAS  PubMed  Google Scholar 

  38. Verger, E., Gil, M., Yaya, R., Viñolas, N., Villà, S., Pujol, T., et al. (2005). Temozolomide and concomitant whole brain radiotherapy in patients with brain metastases: a phase II randomized trial. International Journal of Radiation Oncology Biology Physics, 61(1), 185–191.

    Article  CAS  Google Scholar 

  39. Christodoulou, C., Bafaloukos, D., Linardou, H., Aravantinos, G., Bamias, A., Carina, M., et al. (2005). Temozolomide (TMZ) combined with cisplatin (CDDP) in patients with brain metastases from solid tumors: a Hellenic Cooperative Oncology Group (HeCOG) phase II study. Journal of Neuro-Oncology, 71(1), 61–65.

    Article  CAS  PubMed  Google Scholar 

  40. Trudeau, M. E., Crump, M., Charpentier, D., Yelle, L., Bordeleau, L., Matthews, S., et al. (2006). Temozolomide in metastatic breast cancer (MBC): a phase II trial of the National Cancer Institute of Canada - Clinical Trials Group (NCIC-CTG). Annals of Oncology, 17(6), 952–956.

    Article  CAS  PubMed  Google Scholar 

  41. Siena, S., Crinò, L., Danova, M., Del Prete, S., Cascinu, S., Salvagni, S., et al. (2010). Dose-dense temozolomide regimen for the treatment of brain metastases from melanoma, breast cancer, or lung cancer not amenable to surgery or radiosurgery: a multicenter phase II study. Annals of Oncology, 21(3), 655–661.

    Article  CAS  PubMed  Google Scholar 

  42. Kouvaris, J. R., Miliadou, A., Kouloulias, V. E., Kolokouris, D., Balafouta, M. J., Papacharalampous, X. N., et al. (2007). Phase II study of temozolomide and concomitant whole-brain radiotherapy in patients with brain metastases from solid tumors. Onkologie, 30(7), 361–366.

    CAS  PubMed  Google Scholar 

  43. Melisko, M. E., Anderson, M., Scott, J., Park, J.W., Rugo, H.S. (2009). Phase II study of irinotecan (IN) and temozolomide (TMZ) in breast cancer patients (pts) with brain metastases (BM) or leptomeningeal disease (LMD) that has progressed after stereotactic radiosurgery (SRS) or whole brain radiation (WBRT). Meeting abstract. http://meetinglibrary.asco.org/content/40353-70. Accessed 9 November 2015.

  44. Addeo, R., De Rosa, C., Faiola, V., Leo, L., Cennamo, G., Montella, L., et al. (2008). Phase 2 trial of temozolomide using protracted low-dose and whole-brain radiotherapy for nonsmall cell lung cancer and breast cancer patients with brain metastases. Cancer, 113(9), 2524–2531.

    Article  CAS  PubMed  Google Scholar 

  45. Iwamoto, F. M., Omuro, A. M., Raizer, J. J., Nolan, C. P., Hormigo, A., Lassman, A. B., et al. (2008). A phase II trial of vinorelbine and intensive temozolomide for patients with recurrent or progressive brain metastases. Journal of Neuro-Oncology, 87(1), 85–90.

    Article  CAS  PubMed  Google Scholar 

  46. Cao, K. I., Lebas, N., Gerber, S., Levy, C., Le Scodan, R., Bourgier, C., et al. (2015). Phase II randomized study of whole-brain radiation therapy with or without concurrent temozolomide for brain metastases from breast cancer. Annals of Oncology, 26(1), 89–94.

    Article  CAS  PubMed  Google Scholar 

  47. Pitz, M. W., Desai, A., Grossman, S. A., & Blakeley, J. O. (2011). Tissue concentration of systemically administered antineoplastic agents in human brain tumors. Journal of Neuro-Oncology, 104(3), 629–638.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  48. Pardridge, W. M. (2007). Blood-brain barrier delivery. Drug Discovery Today, 12(1–2), 54–61.

    Article  CAS  PubMed  Google Scholar 

  49. Qin, D. X., Zheng, R., Tang, J., Li, J. X., & Hu, Y. H. (1990). Influence of radiation on the blood-brain barrier and optimum time of chemotherapy. Interntional Journal of Radiation Oncology, Biology, Physics., 19(6), 1507–1510.

    Article  CAS  Google Scholar 

  50. Rubin, P., Gash, D. M., Hansen, J. T., Nelson, D. F., & Williams, J. P. (1994). Disruption of the blood-brain barrier as the primary effect of CNS irradiation. Radiotherapy and Oncology, 31(1), 51–60.

    Article  CAS  PubMed  Google Scholar 

  51. Qin, D., Ma, J., Xiao, J., & Tang, Z. (1997). Effect of brain irradiation on blood-CSF barrier permeability of chemotherapeutic agents. American Journal of Clinical Oncology, 20(3), 263–265.

    Article  CAS  PubMed  Google Scholar 

  52. d’Avella, D., Cicciarello, R., Angileri, F. F., Lucerna, S., La Torre, D., & Tomasello, F. (1998). Radiation-induced blood-brain barrier changes: pathophysiological mechanisms and clinical implications. Acta Neurochirurgica Supplement, 71, 282–284.

    PubMed  Google Scholar 

  53. Van Vulpen, M., Kal, H. B., Taphoorn, M. J., & El-Sharouni, S. Y. (2002). Changes in blood-brain barrier permeability induced by radiotherapy: implications for timing of chemotherapy? Oncology Reports, 9(4), 683–688.

    PubMed  Google Scholar 

  54. Khatri, A., Gaber, M. W., Brundage, R. C., Naimark, M. D., Hanna, S. K., Stewart, C. F., et al. (2011). Effect of radiation on the penetration of irinotecan in rat cerebrospinal fluid. Cancer Chemotherapy and Pharmacology, 68(3), 721–731.

    Article  CAS  PubMed  Google Scholar 

  55. Fang, L., Sun, X., Song, Y., Zhang, Y., Li, F., Xu, Y., et al. (2015). Whole-brain radiation fails to boost intracerebral gefitinib concentration in patients with brain metastatic non-small cell lung cancer: a self-controlled, pilot study. Cancer Chemotherapy and Pharmacology, 76(4), 873–877.

    Article  CAS  PubMed  Google Scholar 

  56. Zeng, Y., Liao, H., Qin, T., Zhang, L., Wei, W. D., Liang, J. Z., et al. (2015). Blood-brain barrier permeability of gefitinib in patients with brain metastases from non-small-cell lung cancer before and during whole brain radiation therapy. Oncotarget, 6(10), 8366–8376.

    Article  PubMed  PubMed Central  Google Scholar 

  57. Bartsch, R., Berghoff, A. S., & Preusser, M. (2014). Breast cancer brain metastases responding to primary systemic therapy with T-DM1. Journal of Neuro-Oncology, 116(1), 205–206.

    Article  PubMed  Google Scholar 

  58. Gerstner, E. R., & Fine, R. L. (2007). Increased permeability of the blood-brain barrier to chemotherapy in metastatic brain tumors: establishing a treatment paradigm. Journal of Clinical Oncology, 25(16), 2306–2312.

    Article  PubMed  Google Scholar 

  59. Adkins, C. E., Mittapalli, R. K., Manda, V. K., Nounou, M. I., Mohammad, A. S., Terrell, T. B., et al. (2013). P-glycoprotein mediated efflux limits substrate and drug uptake in a preclinical brain metastases of breast cancer model. Frontiers in Pharmacology. doi:10.3389/fphar.2013.00136.

    PubMed  PubMed Central  Google Scholar 

  60. Parrish, K. E., Sarkaria, J. N., & Elmquist, W. F. (2015). Improving drug delivery to primary and metastatic brain tumors: strategies to overcome the blood-brain barrier. Clinical Pharmacology and Therapeutics, 97(4), 336–346.

    Article  CAS  PubMed  Google Scholar 

  61. Lockman, P. R., Mittapalli, R. K., Taskar, K. S., Rudraraju, V., Gril, B., Bohn, K. A., et al. (2010). Heterogeneous blood-tumor barrier permeability determines drug efficacy in experimental brain metastases of breast cancer. Clinical Cancer Research, 16(23), 5664–5678.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  62. Wang, M. L. H., Yung, A. W. K., Royce, M. E., et al. (2001). Capecitabine for 5-fluorouracil-resistantbrain metastases from breast cancer. American Journal of Clinical Oncology, 24(4), 421–424.

    Article  CAS  PubMed  Google Scholar 

  63. Siegelmann-Danieli, N., Stein, M., & Bar-Ziv, J. (2003). Complete response of brain metastases originating in breast cancer to capecitabine therapy. Israel Medical Association Journal, 5(11), 833–834.

    PubMed  Google Scholar 

  64. Fabi, A., Vidiri, A., Ferretti, G., Felici, A., Papaldo, P., Carlini, P., et al. (2006). Dramatic regression of multiple brain metastases from breast cancer with capecitabine: another arrow at the bow? Cancer Investigation, 24(4), 466–468.

    Article  CAS  PubMed  Google Scholar 

  65. Bachelot, T., Romieu, G., Campone, M., Dieras, V., Cropet, C., Dalenc, F., et al. (2013). Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (LANDSCAPE): a single-group phase 2 study. Lancet Oncology, 14(1), 64–71.

    Article  CAS  PubMed  Google Scholar 

  66. Morikawa, A., Peereboom, D. M., Thorsheim, H. R., Samala, R., Balyan, R., Murphy, C. G., et al. (2015). Capecitabine and lapatinib uptake in surgically resected brain metastases from metastatic breast cancer patients: a prospective study. Neuro Oncology, 17(2), 289–295.

    Article  PubMed  Google Scholar 

  67. Eli Lilly Web Site. Lilly receives FDA breakthrough therapy designation for abemaciclib—a CDK 4 and 6 inhibitor—in advanced breast cancer. Press release. https://investor.lilly.com/releasedetail.cfm?ReleaseID=935735. Accessed 9 November 2015.

  68. Raub, T. J., Wishart, G. N., Kulanthaivel, P., Staton, B. A., Ajamie, R. T., Sawada, G. A., et al. (2015). Brain exposure of two selective dual CDK4 and CDK6 inhibitors and the antitumor activity of CDK4 and CDK6 inhibition in combination with temozolomide in an intracranial glioblastoma xenograft. Drug Metabolism and Disposition, 43(9), 1360–1367.

    Article  CAS  PubMed  Google Scholar 

  69. Stemmler, H. J., Schmitt, M., Willems, A., Bernhard, H., Harbeck, N., & Heinemann, V. (2007). Ratio of trastuzumab levels in serum and cerebrospinal fluid is altered in HER2-positive breast cancer patients with brain metastases and impairment of blood-brain barrier. Anti-Cancer Drugs, 18(1), 23–28.

    Article  CAS  PubMed  Google Scholar 

  70. Torres, S., Maralani, P., & Verma, S. (2014). Activity of T-DM1 in HER-2 positive central nervous system breast cancer metastases. BMJ Case Reports. doi:10.1136/bcr-2014-205680.

    PubMed  Google Scholar 

  71. Eicher, A. F., Chung, E., Kodack, D., Loeffler, J., Fukumura, D., & Jain, R. (2011). The biology of brain metastases-translation to new therapies. Nature Reviews Clinical Oncology, 8(6), 344–356.

    Google Scholar 

  72. Besse, B., Lasserre, S., Compton, P., Huang, J., Augustus, S., & Rohr, U.-P. (2010). Bevacizumab safety in patients with central nervous system metastases. Clinical Cancer Research, 16(1), 269–278.

    Article  CAS  PubMed  Google Scholar 

  73. Socinski, M. A., Langer, C. J., Huang, J. E., Kolb, M. M., Compton, P., Wang, L., et al. (2009). Safety of bevacizumab in patients with non-small-cell lung cancer and brain metastases. Journal of Clinical Oncology, 27, 5255–5261.

    Article  CAS  PubMed  Google Scholar 

  74. Polikoff, J., Hainsworth, J. D., Fehrenbacher, L., Royer-Joo, S., Mu, Y., Strickland, D. K., & Miller, V. A. (2008). Safety of bevacizumab (Bv) therapy in combination with chemotherapy in subjects with non-small cell lung cancer (NSCLC) treated on ATLAS. Journal of Clinical Oncology, 26(15 Suppl), a8079.

    Google Scholar 

  75. De Braganca, K. C., Janjigian, Y. Y., Azzoli, C. G., Kris, M. G., Pietanza, M. C., Nolan, C. P., et al. (2010). Efficacy and safety of bevacizumab in active brain metastases from non-small cell lung cancer. Journal of Neuro-Oncology, 100(3), 443–447.

    Article  PubMed  PubMed Central  Google Scholar 

  76. Lukas, R. V., Gabikian, P., Garza, M., & Chmura, S. J. (2014). Treatment of brain metastases. Oncology, 87(6), 321–329.

    Article  CAS  PubMed  Google Scholar 

  77. Lin, N.U., Gelman, R.S., Younger, W.J., Sohl, J., Freedman, R.A., Sorenson, A. G., et al. (2013). Phase II trial of carboplatin (C) and bevacizumab (BEV) in patients (pts) with breast cancer brain metastases (BCBM). Journal of Clinical Oncology, 31(suppl), abstr 513.

  78. Lu, Y. S., Chen, T. W., Lin, C. H., et al. (2015). Bevacizumab preconditioning followed by etoposide and cisplatin is highly effective in treating brain metastases of breast cancer progressing from whole-brain radiotherapy. Clinical Cancer Research, 21(8), 1851–8.

    Article  CAS  PubMed  Google Scholar 

  79. Kreuter, J. (2014). Drug delivery to the central nervous system by polymeric nanoparticles: what do we know? Advances in Drug Delivery Reviews. doi:10.1016/j.addr.2013.08.008.

    Google Scholar 

  80. Patel, T., Zhou, J., Piepmeier, J. M., & Saltzman, W. M. (2012). Polymeric nanoparticles for drug delivery to the central nervous system. Advances in Drug Delivery Reviews, 64(7), 701–705.

    Article  CAS  Google Scholar 

  81. Anders, C. K., Adamo, B., Karginova, O., Deal, A. M., Rawal, S., et al. (2013). Pharmacokinetics and efficacy of PEGylated liposomal doxorubicin in an intracranial model of breast cancer. PloS One. doi:10.1371/journal.pone.0061359.

  82. Hoch, U., Staschen, C.-M., Johnson, R., & Eldon, M. A. (2014). Nonclinical pharmacokinetics and activity of etirinotecan pegol (NKTR-102), a long-acting topoisomerase 1 inhibitor, in multiple cancer models. Cancer Chemotherapy and Pharmacology, 74(6), 1125–1137.

  83. Gaillard, P. J., Appeldoorn, C. C., Dorland, R., van Kregten, J., Manca, F., Vugts, D., et al. (2014). Pharmacokinetics, brain delivery, and efficacy in brain tumor-bearing mice of glutathione pegylated liposomal doxorubicin (2B3-101). PloS One. doi:10.1371/journal.pone.0082331.

  84. Gulyaev, A. E., Gelperina, S. E., Skidan, I. N., Antropov, A. S., Kivman, G. Y., & Kreuter, J. (1999). Significant transport of doxorubicin into the brain with polysorbate 80-coated nanoparticles. Pharmaceutical Research, 16(10), 1564–1569.

    Article  CAS  PubMed  Google Scholar 

  85. Wohlfart, S., Khalansky, A. S., Gelperina, S., Begley, D., Kreuter, J., et al. (2011). Kinetics of transport of doxorubicin bound to nanoparticles across the blood-brain barrier. Journal of Controlled Release, 154(1), 103–107.

    Article  CAS  PubMed  Google Scholar 

  86. Steiniger, S. C., Kreuter, J., Khalansky, A. S., Skidan, I. N., Bobruskin, A. I., Smirnova, Z. S., et al. (2004). Chemotherapy of glioblastoma in rats using doxorubicin-loaded nanoparticles. International Journal of Cancer, 109(5), 759–767.

    Article  CAS  PubMed  Google Scholar 

  87. Gelperina, S., Maksimenko, O., Khalansky, A., Vanchugova, L., Shipulo, E., Abbasova, K., et al. (2010). Drug delivery to the brain using surfactant-coated poly(lactide-co-glycolide) nanoparticles: influence of the formulation parameters. European Journal of Pharmaceutics and Biopharmaceutics, 74(2), 157–163.

    Article  CAS  PubMed  Google Scholar 

  88. Gao, K., & Jiang, X. (2006). Influence of particle size on transport of methotrexate across blood brain barrier by polysorbate 80-coated polybutylcyanoacrylate nanoparticles. International Journal of Pharmacy, 310(1–2), 213–219.

    Article  CAS  Google Scholar 

  89. Wang, C. X., Huang, L. S., Hou, L. B., Jiang, L., Yan, Z. T., Wang, Y. L., et al. (2009). Antitumor effects of polysorbate-80 coated gemcitabine polybutylcyanoacrylate nanoparticles in vitro and its pharmacodynamics in vivo on C6 glioma cells of a brain tumor model. Brain Research. doi:10.1016/j.brainres.2009.01.011.

  90. Hoch, U., Nounou, M.I., Adkins, C.E., Terrell, T.B., Villalba, H., Eldon, M.E., et al. (2013). Etirinotecan pegol prolongs survival in an experimental model of brain metastases of human triple negative breast cancer. European Cancer Congress 2013; Abstr 1915.

  91. Mittapalli, R. K., Liu, X., Adkins, C. E., Nounou, M. I., Bohn, K. A., Terrell, T. B., et al. (2013). Paclitaxel-hyaluronic nanoconjugates prolong overall survival in a preclinical brain metastases of breast cancer model. Molecular Cancer Therapeutics, 12(11), 2389–2399.

    Article  CAS  PubMed  Google Scholar 

  92. Linot, B., Campone, M., Augereau, P., Delva, R., Abadie-Lacourtoisie, S., Nebout-Mesgouez, N., et al. (2014). Use of liposomal doxorubicin-cyclophosphamide combination in breast cancer patients with brain metastases: a monocentric retrospective study. Journal of Neuro-Oncology, 117(2), 253–259.

    Article  CAS  PubMed  Google Scholar 

  93. Perez, E. A., Awada, A., O'Shaughnessy, J., Rugo, H. S., Twelves, C., Im, S. A., et al. (2015). Etirinotecan pegol (NKTR-102) versus treatment of physician's choice in women with advanced breast cancer previously treated with an anthracycline, a taxane, and capecitabine (BEACON): a randomised, open-label, multicentre, phase 3 trial. Lancet Oncology, 16(15), 1556–68.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

Writing assistance was provided by the Phillips Gilmore Oncology Communications. Financial support for the writing assistance was provided by the Nektar Therapeutics.

Author information

Authors and Affiliations

  1. Mayo Clinic, 200 First St SW, Rochester, MN, 55905, USA

    Minetta C. Liu

  2. Ramon y Cajal University Hospital, Madrid, Spain

    Javier Cortés

  3. Vall D’Hebron Institute of Oncology, Barcelona, Spain

    Javier Cortés

  4. Baylor-Sammons Cancer Center, Texas Oncology, U.S. Oncology, Dallas, TX, USA

    Joyce O’Shaughnessy

Authors
  1. Minetta C. Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Javier Cortés
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Joyce O’Shaughnessy
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Minetta C. Liu.

Ethics declarations

Disclosures

Drs. O’Shaughnessy and Cortes serve on the Steering Committee for the BEACON phase III trial.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Liu, M.C., Cortés, J. & O’Shaughnessy, J. Challenges in the treatment of hormone receptor-positive, HER2-negative metastatic breast cancer with brain metastases. Cancer Metastasis Rev 35, 323–332 (2016). https://doi.org/10.1007/s10555-016-9619-z

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10555-016-9619-z

Keywords

Search

Navigation